Chunfeng Lu
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Nrf2 activation is required for curcumin to induce lipocyte phenotype in hepatic stellate cells.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 04, 2017
Nrf2 induces lipocyte phenotype via a SOCS3-dependent negative feedback loop on JAK2/STAT3 signaling in hepatic stellate cells.
Journal: International immunopharmacology
Published: April 04, 2017
Blockade of hedgehog pathway is required for the protective effects of magnesium isoglycyrrhizinate against ethanol-induced hepatocyte steatosis and apoptosis.
Journal: IUBMB life
Published: March 13, 2017
Nrf2 Activation Is Required for Ligustrazine to Inhibit Hepatic Steatosis in Alcohol-Preferring Mice and Hepatocytes.
Journal: Toxicological sciences : an official journal of the Society of Toxicology
Published: November 12, 2016
Nrf2 Knockdown Disrupts the Protective Effect of Curcumin on Alcohol-Induced Hepatocyte Necroptosis.
Nrf2 Knockdown Disrupts the Protective Effect of Curcumin on Alcohol-Induced Hepatocyte Necroptosis.
Journal: Molecular pharmaceutics
Published: November 01, 2016
Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
Journal: Toxicology and applied pharmacology
Published: September 10, 2016
Inhibition of YAP signaling contributes to senescence of hepatic stellate cells induced by tetramethylpyrazine.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: August 19, 2016
Optimization of Sample Points for Monitoring Arable Land Quality by Simulated Annealing while Considering Spatial Variations.
Journal: International journal of environmental research and public health
Published: July 10, 2016
Nrf2 knockdown attenuates the ameliorative effects of ligustrazine on hepatic fibrosis by targeting hepatic stellate cell transdifferentiation.
Journal: Toxicology
Published: May 30, 2016
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
Journal: The FEBS journal
Published: May 08, 2016
Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway.
Journal: IUBMB life
Published: September 14, 2015
Last Updated: 09/26/2026